Johnson & Johnson (JNJ BE) stock market data APIs
€150.3048
1.18(0.8%)
as of September 15, 2025
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.BE.
Prev. Close
150.3048
Open
151.4894
High
151.4894
Low
150.3048
52 wk Range
128.1918-158.0441
Market Cap
385 769 M
Dividends (Yield)
0.0224
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?
Shares of Intuitive Surgical ISRG have been declining since the stock touched an all-time high of $616.00 on Jan. 23, 2025. The company’s shares have lost 13.4% in the past three months, underperfor...
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
21 abstracts from across the Company's portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and schizophrenia New Phase 3 data demonstrate the...
Jim Cramer Says Procter & Gamble Stock is “Still Way Too High”
The Procter & Gamble Company (NYSE:PG) is one of the stocks Jim Cramer shared insights on. Cramer said the stock is not “weak enough,” as he commented: “I didn’t include Procter & Gamble and ...
How Strong Is Johnson & Johnson’s Value After FDA Nod for New Drug in 2025?
Deciding what to do with Johnson & Johnson stock? You are not alone. Over the past year, plenty of investors have been trying to figure out if now is the time to buy, hold, or sell, especially as the ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
